Objective: To evaluate the efficacy and safety of administering quetiapine once vs twice daily.
Q uetiapine, a second-generation antipsychotic agent, has shown efficacy and safety in the treatment of patients with schizophrenia experiencing an acute exacerbation of their illness (1, 2) . Further, pharmacokinetic data suggest quetiapine has a plasma half-life of nearly 6 hours, which is slightly increased with multiple dosing. Thus, in spite of an elimination half-life that averages 6 hours (range 5.8 to 6.8 hours [3] ), quetiapine has been shown to be therapeutically equivalent when dosed at either 2 or 3 times daily (4) .
Among the key pharmacokinetic variables that guide dosing of a drug are its plasma elimination half-life, the presence or absence of active metabolites, whether the drug exhibits linear pharmacokinetics, and the time taken to achieve steady-state levels of the drug. Therefore, quetiapine, which exhibits a linear pharmacokinetic profile over its therapeutic dosage range (150 to 750 mg daily), reaches steady-state plasma levels in 2 days. To maintain these steady-state plasma levels, it would follow that quetiapine needs to be administered 2 or 3 times daily. However, there is no known one-to-one correspondence between plasma levels of a drug and its levels in the central nervous system (CNS) or, for that matter, between plasma levels and drug-receptor occupancy. Further, recent positron emission tomography (PET) data suggest that neither high rates of dopamine (D 2 ) receptor occupancy nor sustained blockade of these receptors is necessary for antipsychotic efficacy (5) . These new PET data have led to the concepts of tight (for example, haloperidol) vs loose (for example, clozapine and quetiapine) D 2 receptor binding and sustained (for example, haloperidol) vs transient and surmountable (for example, clozapine and quetiapine) blockade of D 2 receptors to explain the rationale for the efficacy of the second-generation antipsychotic agents, such as clozapine and quetiapine. One corollary to this hypothesis would be to test the dosing frequency of drugs such as clozapine and quetiapine at less frequent intervals than predicted by their pharmacologic half-lives. If quetiapine, with a relatively short elimination half-life, could be dosed as a single daily dose, it might result in a greater adherence to treatment by patients in the long term. The objective of this study was to evaluate whether quetiapine fumarate dosed once a day was therapeutically equivalent to twice-daily dosing in subjects who had reached a stable therapeutic dose.
Methods

Study Design
The trial comprised 3 phases, each of 4 weeks' duration. The first phase (from baseline, time 0, to visit 4 , week 4) involved withdrawal of the previous antipsychotic agent (over 7 to 14 days) as quetiapine was initiated (50 to 100 mg daily) and increased to either 400 or 600 mg daily during the next 7 to 10 days. Once the target dose was achieved (either 400 or 600 mg), quetiapine was administered as 200 mg twice daily (400 mg daily) or 200 mg in the morning and 400 mg in the evening (600 mg daily) for an additional 2 weeks. The second phase of the study (from visit 4, week 4, to visit 8, week 8) was double blind and involved the random assignment (1:1 ratio) to either once-or twice-daily treatment with quetiapine. The once-daily group received either 400 mg or 600 mg at bedtime and one placebo tablet in the morning. The twice-daily group received 200 mg twice daily (along with a placebo tablet at bedtime) for the 400 mg daily group or 200 mg and 400 mg (and a placebo) at bedtime for the 600 mg daily group. This phase lasted 4 weeks. The next phase was also double-blind (from visit 8, week 8, to visit 10, week 12) and involved a crossover for 4 additional weeks. The once-daily group was crossed over to twice daily and vice versa. At the end of this double-blind phase, subjects were dosed openly with quetiapine at either 400 or 600 mg given as a single bedtime dose (or twice daily if they so chose) until they were discharged.
Baseline screening assessments, medical history, and psychiatric history were recorded after written informed consent was obtained from participants. Patients with a diagnosis of schizoaffective disorder were permitted to continue mood stabilizers, either lithium, valproate, or antidepressant medications, unchanged in dosage throughout the double-blind phase. Lorazepam (up to 4 mg daily) was permitted for episodic agitation on an as-needed basis, as were hypnotic agents for insomnia. After the withdrawal of routine antiparkinsonian agents (1 week following the last dosage of the previous antipsychotic agent), their use was permitted only for newly emergent extrapyramidal symptoms (EPS) based on clinical judgement and after ratings for EPS were completed.
Patient Population
Eligible subjects were men and women of any ethnicity aged 18 to 65 years with DSM-IV (6) diagnoses of either schizophrenia (except the catatonic subtype) or schizoaffective disorder who had provided informed consent. They were required to have a Positive and Negative Symptom Scale (PANSS) (7) total score of ³ 60 but £ 120 and a Clinical Global Impression (CGI) severity score ³ 4 (8); to pass laboratory screening, ECG, slit-lamp ophthalmological, and physical examinations; and to be clinically appropriate candidates for quetiapine treatment. These subjects were referred by their attending psychiatrists, as the current antipsychotic treatments were ineffective (6 to 8 weeks of prior treatment) for these subjects.
Pregnant or lactating women or women of reproductive age without adequate contraception were excluded, as were subjects considered to be actively suicidal or homicidal. Those
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Assessments
Psychopathology and its severity was assessed at scheduled intervals starting at the baseline through week 12, using the PANSS, CGI Scale, and the 21 item Hamilton Depression Rating Scale (HDRS; 9). EPS, akathisia, and tardive dyskinesia (TD) were assessed at the same time points as the psychopathology measures, using the Simpson Angus Neurological Rating Scale, Barnes Akathisia Scale (BA), and Abnormal Involuntary Movement Scale (AIMS), respectively (10) (11) (12) . General Assessment of Functioning (GAF; DSM-IV, Axis V) scores were assessed at baseline and exit from the double-blind phase. Adverse events, whether spontaneously reported or in response to an open-ended question, were recorded, and orthostatic blood pressure and pulse were recorded at each visit. Body weight was recorded at quetiapine initiation (that is, baseline) and at the end of the double-blind study.
Statistical Analysis
The primary outcome of the study was to examine the differences, if any, in the therapeutic efficacy between once-vs twice-daily quetiapine administration regimens. A priori, the primary efficacy measure was defined as a ³ 30% reduction in the total PANSS score from baseline to the last visit in the double-blind phase. The differences between the proportion of subjects meeting the a priori response criteria were compared in the two quetiapine dosing administration groups, using contingency statistics.
A 1-way repeated-measures analysis of variance (ANOVA) was used to examine the relation between successive PANSS total scores and subscale scores at weeks 0, 4, 8, and 12 in the study sample as a whole, as well as in the groups assigned to once-or twice-daily administration separately. If the main effect was significant, post hoc pairwise differences between visit mean changes were examined using Bonferroni's adjustment for multiple comparisons. Subsequently, a mixed-model, repeated-measures ANOVA with the clinical measures (PANSS total or subscale scores) as the withinsubject factor and the randomly assigned (once or twice daily) as the between-subject factor was performed to examine the interaction between the 2 factors.
PANSS subscale change scores, as well as change scores for the HDRS, CGI severity, and GAF, were analyzed for the entire group using the last observation carried forward (LOCF) method rather than a "completers" analysis. However, it is pertinent to note that only 2 of 21 randomized subjects dropped out at the penultimate visit of the double-blind phase of the study and that their data were carried forward to the last visit.
Results
Baseline Characteristics
The demography and illness characteristics for the 21 subjects are summarized in Table 1 . In terms of switching from the previous antipsychotic agents, 13 were switched from first-generation agents, 4 were switched from risperidone, and 4 were switched from olanzapine. Among the 14 subjects with schizoaffective disorder, 2 were receiving lithium, 8 were receiving valproic acid, and 5 were receiving antidepressants.
Patient Disposition
Four subjects were titrated and stabilized at a daily dosage of 400 mg of quetiapine; the 17 remaining subjects achieved the daily dosage of 600 mg. Nineteen of these 21 subjects completed the 2-month double-blind phase, whereas 1 subject in each of those assigned to either the once-or twice-daily treatment arms reached the penultimate visit and was dropped from the study owing to worsening of their illness during the crossover phase (Figures 1 and 2 ). Another subject assigned initially to the twice-daily dosing had not shown clinical improvement and also worsened at the crossover point to once-daily dosing but completed the double-blind phase ( Figure 2 ).
Efficacy Analyses
There were no statistically significant differences between the number of patients who met the PANSS response criteria in the once-daily quetiapine administration group (8/10 subjects) when compared with the group treated with twice-daily quetiapine (7/11 subjects). Three of the 4 subjects stabilized at 400 mg daily met the response criteria, and 12 of 17 subjects stabilized at 600 mg daily met the response criteria. In the group as a whole, 15 of 21 subjects (70%) met the response criteria. 
Secondary Analyses
PANSS total scores in the group as a whole showed significant improvement on quetiapine treatment (F = 40.6, df 2.2, 46.9, P < 0.0005) with Huynh-Feldt correction. Post hoc pairwise comparisons were all significant (P < 0.05 to P < 0.0005), except for the difference between week 8 and week 12; that is, most of the improvement had occurred by week 8. Similar results were obtained when the data for PANSS total scores were analyzed separately for those assigned to once-vs twice-daily dosing with quetiapine ( Table 2 ).
The total and subscale change scores of PANSS and other efficacy assessments are presented in Tables 2 and 3 group as well as for those assigned to either once-or twice-daily dosing with quetiapine. The LOCF analyses for the entire group showed a significant improvement in the PANSS total and subscale scores, as well as the CGI severity scores, HDRS scores, and GAF scores.
Safety Analyses Clinical Course at the Study Switchover Points, Including
Study Withdrawals. The initial dosing switch occurred from the twice-daily (open) phase to the randomization (double-blind) phase. At this switch point, 10 of the 21 subjects were switched to once daily, and 11 subjects continued on the twice-daily regimen. None of the 10 subjects randomized to the once-daily dosing worsened at this switch point as can be noted in Figure 1 . The next switch point occurred 4 weeks later and involved a crossover of the dosing regimen. At this point, 3 subjects showed worsening of clinical symptoms. Two subjects who switched from twice daily to once daily (2/11, 18%) evidenced worsening of symptoms, and one subject switched from once-to the twice-daily dosing regimen (1/10, 10%) deteriorated clinically.
The final switchover point occurred at the end of the double-blind phase. Among 15 responding subjects, 14 voluntarily chose the once-daily open treatment, and 1 subject chose the twice-daily regimen. None of the 15 subjects worsened at this switch point.
Additional Safety Evaluation. Adverse effects elicited or reported during the titration and stable administration periods and the double-blind period, at a rate of at least 1 subject (that is, 5%) or more were somnolence (5/21, 24%), headache (4/21, 19%), dizziness (3/21, 14%), constipation (1/21, 5%), urinary incontinence (1/21, 5%), and insomnia (1/21, 5%). These adverse effects were noted mostly in the first 4 to 8 weeks of treatment and were of mild-to-moderate severity. These events did not lead to withdrawal from the study, either resolved in time or with symptomatic treatment, and did not reoccur during the crossover phase, except for somnolence in 1 subject, intermittent headache in 1 subject, and constipation in 1 subject. Symptomatic postural hypotension was noted in 4 subjects (19%) during the titration phase of the study. For 2 of these 4 subjects, symptomatic postural hypotension recurred in the crossover phase of the blinded study. These events occurred during the crossover from once-to twice-daily dosing or vice versa.
Five subjects experienced akathisia at baseline, and 5 subjects evidenced EPS at baseline. Four subjects had TD (using research diagnostic criteria for TD [13] ) at baseline. Akathisia resolved in all subjects by 4 weeks of quetiapine treatment, and EPS resolved in 6 to 8 weeks of treatment. No new cases of akathisia or other EPS were noted in the double-blind phases of the study. Two of the 4 subjects with TD showed evidence of worsening (withdrawal dyskinesia) for up to 6 weeks but, by the end of the double-blind study, had AIMS scores lower than at baseline. The other 2 subjects with TD at baseline showed a gradual and steady improvement of the scores during the study. All 4 subjects had lower AIMS scores by the end of the study (data not shown).
The mean body weight for the entire group was 87.7 kg (SD 17. (t = 2.9, df 20, P = 0.008). The weight gain was noted over a duration of 11 to 12 weeks of quetiapine treatment, and it is important to note all subjects with schizoaffective disorders were also receiving either mood stabilizers or antidepressant medicines as concomitant therapy.
During the double-blind phase, there were 27 doses of lorazepam dispensed for episodic agitation or anxiety. These differences were not statistically significant between the once-and twice-daily administration groups and occurred mainly in the first 4 weeks of treatment. There were only 3 instances of anticholinergic use for EPS: once in a person receiving once-daily treatment and twice in subjects assigned to twice-daily dosing. These instances occurred shortly after the switch from the previous antipsychotic agents during the open-titration and stabilization phase.
Adherence to Medications
As all subjects were inpatients, study tablets and other medications were dispensed by nursing staff, and pill counts revealed > 98% adherence to treatment.
Discussion
These preliminary data suggest that most subjects who had reached a therapeutic dose of quetiapine fumarate (400 or 600 mg daily) on a twice-daily administration schedule were switched to the once-daily regimen without significant difficulty. A minority (3/21, 15%) of subjects worsened clinically during the switch, and so it would be clinically prudent to closely monitor subjects for the first 2 to 4 weeks after the switch to once-daily administration.
Just prior to the initiation of the double-blind randomization phase, all subjects were receiving the twice-daily regimen, and 10 subjects were randomized to the once-daily regimen, whereas 11 continued on the twice-daily regimen. None of the 10 subjects randomized to once-daily administration at this point experienced any worsening of symptoms. Four weeks later, at the crossover point, 2 subjects showed evidence of worsening after initial improvement. Based on the initial improvement and worsening shortly following the switch, it is likely that the temporal deterioration in these 2 subjects was associated with the change in the administration schedule. One occurred in a subject crossing from the once-to twice-daily regimen (1/10, 10%) and another in a subject moving from twice-to once-daily regimen (1/11, 9%). Is it possible that supersensitivity has a role to play in these patients (14)? Subjects who had received the previous oral antipsychotic agents for 6 to 8 weeks were tapered off their medicines in 1 to 2 weeks, and the phenomena were noted within 6 weeks (15). Thus, in sensitive individuals who have shown the need for escalating dosages of first-generation neuroleptic agents in the recent past, have increased psychotic symptoms just before a depot neuroleptic injection, or have symptoms of schizophrenia that are different from earlier exacerbations on medication withdrawal may show deterioration in the switching over to quetiapine. In such individuals a slower switch may be appropriate. Interestingly, and similar to the experience of Chouinard and others (16) in treating supersensitivity psychoses, we too noted significant improvement with clozapine in 2 patients who worsened at the switchover point in the current study.
A third subject assigned to the twice-daily regimen, who had not improved through the first 4 weeks of double-blind treatment, worsened at the crossover but stayed the course through the next 4 weeks. While it is possible that the worsening of symptoms in this last subject was caused by the switch in administration schedule, it is also likely that this clinical worsening was associated with the natural course of the illness.
In some subjects, attention to sedation and postural hypotension is clinically advisable both during the titration phase and following the switch to once-daily administration, especially among those subjects who are treated with antihypertensive medicines or have diabetes mellitus. However, in most subjects, administration of the entire dose of quetiapine at bedtime may help minimize the risk of orthostatic hypotension and sedation, as patients are more likely to be recumbent during the peak plasma concentrations of the drug.
It is possible that some subjects switching from agents with an anticholinergic profile to quetiapine could experience a cholinergic rebound, and perhaps a longer taper of the anticholinergic agent may be useful (17) . In some subjects, worsening of the preexisting TD may have been caused by unmasking of TD occurring during a switch from a potent and tight D 2 receptor antagonist (first-generation agents) to (7); b Last observation carried forward; c All tests remained significant even after applying the Bonferroni correction for multiple comparisons ;
d Clinical Global Impression of Severity (8); e Hamilton Depression Rating Scale (9); f quetiapine. However, with the passage of time, the symptoms of TD diminished considerably on continued quetiapine treatment to less than the prequetiapine baseline.
Emerging data sets from PET studies in patients with schizophrenia have begun to suggest that D 2 receptor occupancy by antipsychotic agents need not be very high; further, the question has arisen whether such receptor blockade needs to be sustained continuously (18) . The PET data from patients treated with depot haloperidol injections or oral clozapine and quetiapine-treated subjects would argue otherwise (19, 20) .
A second set of questions raised by recent PET data regarding quetiapine specifically suggest that transiently high D 2 occupancy rates (58% to 64%) may be adequate for treatment response (18) . More recently, the same group also noted that first-episode patients who responded to quetiapine did not differ from those who did not, simply based on peak and trough D 2 receptor occupancy rates (20) .
A third line of support for once-daily administration of relatively short half-life drugs comes from clinical experience in clozapine clinics. Subsets of subjects who have achieved steady-state drug levels and reached stable target dosages of clozapine (that is, those who are not also encumbered by dosage-related adverse effects: seizures, sedation, and postural hypotension) can be switched to a once-daily dosing regimen (mainly for patient convenience and to increase adherence to treatment) without loss of antipsychotic efficacy. These converging lines of evidence provide the rationale for the dosing of quetiapine fumarate as a single daily dose in subjects who have already reached a stable target dosage.
Nonetheless, these preliminary, random-assignment, double-blind clinical data suggest that bedtime administration of quetiapine among patients stabilized at their therapeutic dosage is clinically feasible. A switch to once-daily quetiapine administration can be considered both for the convenience of the subject and to improve adherence to long-term treatment. However, it must be emphasized that these data do not suggest "drug holidays" are good clinical practice but really that administration frequency based on plasma half-lives may not necessarily be valid for all antipsychotic agents.
Résumé : Essai clinique à répartition aléatoire et à double insu sur l'administration une ou deux fois par jour de fumarate de quétiapine chez les patients souffrant de schizophrénie ou de trouble schizo-affectif : une étude pilote Objectif : Évaluer l'efficacité et l'innocuité de l'administration de quétiapine une ou deux fois par jour.
Méthode : Au moyen d'une méthode à double insu, 21 hommes ou femmes hospitalisés souffrant de schizophrénie ou de trouble schizo-affectif conforme aux critères du DSM-IV qui avaient reçu des doses inchangées (pendant 2 semaines) de soit 400 mg, soit 600 mg par jour de quétiapine administrée deux fois par jour, ont été affectés au hasard à l'administration une ou deux fois par jour pendant 4 semaines puis, ont croisé pour la dose opposée pendant 4 autres semaines. La psychopathologie d'usage et des mesures de sécurité ont été utilisées durant l'étude.
Résultats : Presque 70 % (15/21) des sujets ont satisfait aux critères de réponse efficace a priori, sans différences statistiques dans la réponse entre ceux qui étaient affectés à l'administration de quétiapine une fois par jour et ceux qui la recevaient deux fois par jour. Les analyses statistiques ont confirmé que la majorité des sujets maintenaient l'efficacité durant la transition à l'administration une ou deux fois par jour de quétiapine. Une minorité (15 %) a connu une aggravation des symptômes ou une hypotension orthostatique durant le croisement. La quétiapine était généralement bien tolérée, qu'elle soit administrée une ou deux fois par jour.
Conclusions :
Ces données pilotes indiquent qu'il est cliniquement faisable de changer la dose biquotidienne de la majorité des sujets traités à la quétiapine pour un régime quotidien. Une minorité peut connaître une aggravation des symptômes ou une hypotension orthostatique durant la substitution. Cette stratégie consistant à administrer la quétiapine entièrement au coucher peut favoriser l'adhésion au traitement.
